Treatment Response Evaluation by F-18 FDG PET/CT in Radioiodine Refractory Differentiated Carcinoma in a Case with Multiple Unusual Metastatic Lesions

Abstract

F-18 FDG PET/CT has a documented role in diagnosis of the patients with radioiodine refractory differentiated thyroid carcinoma (RAIR-DTC) and there are ongoing studies about the treatment response evaluation for tyrosine kinase inhibitor treatment response evaluation. This case report is about the treatment response evaluation of a unique patient with multiple unusual metastatic lesions of RAIR-DTC.

Keywords

• Radioiodine refractory
• treatment response
• fluorodeoxyglucose

References

1. 1. Sakulpisuti, C., Charoenphun, P., & Chamroonrat, W. (2022). Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer. Molecules, 27(15), 4936. https://doi.org/10.3390/molecules27154936
2. 2. Heydarzadeh, S., Moshtaghie, A. A., Daneshpoor, M., & Hedayati, M. (2020). Regulators of glucose uptake in thyroid cancer cell lines. Cell communication and signaling : CCS, 18(1), 83. https://doi.org/10.1186/s12964-020-00586- x
3. 3. Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., Schuff, K. G., Sherman, S. I., Sosa, J. A., Steward, D. L., Tuttle, R. M., & Wartofsky, L. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association, 26(1), 1–133. https://doi.org/10.1089/thy.2015.0020
4. 4. Takeuchi, S., Shiga, T., Hirata, K., Taguchi, J., Magota, K., Ariga, S., Gouda, T., Ohhara, Y., Homma, R., Shimizu, Y., Kinoshita, I., Tsuji, Y., Homma, A., Iijima, H., Tamaki, N., & Dosaka-Akita, H. (2018). Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study. BMJ open, 8(8), e021001. https://doi.org/10.1136/bmjopen-2017-021001
5. 5. Jannin, A., Lamartina, L., Moutarde, C., Djennaoui, M., Lion, G., Chevalier, B., Vantyghem, M. C., Deschamps, F., Hadoux, J., Baudin, E., Schlumberger, M., Leboulleux, S., & Do Cao, C. (2022). Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival. European journal of nuclear medicine and molecular imaging, 49(7), 2401–2413. https://doi.org/10.1007/s00259-022-05697-w
6. 6. Jain, T. K., Krishnaraju, V. S., Mittal, B. R., Sood, A., Kumar, R., Garg, R., & Kumar, S. (2021). Follicular Thyroid Carcinoma with Unusual Radioiodine-Refractory Breast Metastasis Mimicking Primary Breast Malignancy. Journal of nuclear medicine technology, 49(3), 288–289. https://doi.org/10.2967/jnmt.120.259259
7. 7. Cavaco, D., Fraga, D., & Ferreira, T. (2021). Coexistent thyroid and lung cancers resembling "flip-flop" phenomenon. Clinical case reports, 9(9), e04770. https://doi.org/10.1002/ccr3.4770
8. 8. Zunino, A., Pitoia, F., Faure, E., Reyes, A., Sala, M., Sklate, R., Ilera, V., Califano, I., & Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo (2019). Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases. Endocrine, 65(3), 630–636. https://doi.org/10.1007/s12020-019-01991-0